Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof

一种试剂盒、疾病的技术，应用在疾病诊断、仪器、生物材料分析等方向

Inactive Publication Date: 2015-04-22
CANCER PREVENTION & CURE
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Further, there are no blood tests available today that can detect only the presence of specific lung histopathological states

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
  • Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
  • Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0366] Human blood samples were collected from volunteers. Thirty samples were collected from individuals who were not known to have non-small cell lung cancer or asthma. These 30 samples are included and referred to herein as the "normal population". Twenty-eight blood samples were collected from individuals who were known to have asthma and were diagnosed with it by a physician. These 28 samples contain and are referred to herein as the "asthmatic population". Thirty blood samples were collected from individuals known to have non-small cell lung cancer and diagnosed by a physician. These 30 samples contain and are referred to herein as the "lung cancer population".

[0367] Research is conducted to select biomarkers whose altered expression levels are believed to be associated with lung cancer or asthma. As used herein, "lung cancer" is meant to include those lung cancers known as non-small cell lung cancer. The following 59 biomarkers were selected for testing: CD40, live...

Embodiment 2

[0381] Human blood samples were collected from volunteers. 142 samples were collected from individuals who were not known to have non-small cell lung cancer or asthma. These samples are included and referred to herein as the "normal population". 108 blood samples were collected from individuals known to have asthma and diagnosed by a physician. These samples contain and are referred to herein as the "asthmatic population". 146 blood samples were collected from individuals known to have non-small cell lung cancer and diagnosed by a physician. These samples contain and are referred to herein as the "lung cancer population".

[0382] The same method as described in Example 1 was performed. Figure 2A-2E The results obtained are shown. These results provide guidance for selecting suitable biomarkers for use in the methods of the invention. Specifically, the probability value of a specific marker is useful at this point.

[0383] Figure 2E Shows the probabilities associated with ...

Embodiment 3

[0385] Human blood samples were collected from volunteers. 288 samples were collected from individuals who are not known to have non-small cell lung cancer or asthma. These samples are included and referred to herein as the "normal population". 180 blood samples were collected from individuals who were known to have asthma and were diagnosed with it by a physician. These samples contain and are referred to herein as the "asthmatic population". 360 blood samples were collected from individuals known to have non-small cell lung cancer and diagnosed by a physician. These samples contain and are referred to herein as the "lung cancer population".

[0386] The same method as described in Example 1 was performed. The Panomics’ Procarta Cytokine kit (Cat#PC1017) was also used. Use antibodies against PAI-1 and leptin from two different kits. PAI-1 A And leptin 1 The antibody is produced by Millipore. PAI-1 B The antibody is produced by Panomics. Figure 3A-3E Show the results obta...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides biomarkers and combinations of biomarkers useful in diagnosing lung diseases such as non-small cell lung cancer or reactive airway disease. The invention also provides methods of differentiating lung disease, methods of monitoring therapy, and methods of predicting a subject's response to therapeutic intervention based on the extent of expression of the biomarkers and combinations of biomarkers. Kits comprising agents for detecting the biomarkers and combination of biomarkers are also provided.

Description

[0001] This application is a divisional application of the international application PCT / US2010 / 027243, the international filing date of March 12, 2010, and the Chinese national phase application number 201080017220.5. Background of the invention [0002] (a) Field of invention [0003] The invention relates to the detection, identification, evaluation, prevention, diagnosis and treatment of lung diseases using biomarkers and their kits. More specifically, the present invention relates to the diagnosis of non-small cell carcinoma and reactive airway diseases by measuring and quantifying the expression level of specific markers. The present invention also relates to the identification of biomarkers present in human serum or other biological fluids. When the expression levels of these markers are found to be different from those found in normal populations, they are related to human lung tissue and human respiratory system. Pathology. By identifying the markers associated with thes...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574
CPCG01N33/57423G01N33/6893G01N2800/12G01N2333/96494G01N2800/60G01N2800/52
Inventor R·T·斯特里佩E·伊兹比卡S·H·贝克
Owner CANCER PREVENTION & CURE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap